Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Pharvaris N.V. (PHVS)

Pharvaris N.V. (PHVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Manufacturing, Housing Due Next Week in Canada Baystreet - Fri May 10, 2:50PM CDT

Monday U.S. Featured Earnings Legend Biotech Corporation (NASDAQ: LEGN) (Q1) EPS ...

CRDL.TO : 3.01 (+2.73%)
ORE.TO : 0.85 (+4.94%)
PBH.TO : 92.35 (+3.60%)
LEGN : 42.97 (-0.62%)
STNE : 16.65 (+0.30%)
PHVS : 21.17 (-1.35%)
BABA : 84.60 (+5.70%)
SONY : 76.15 (+1.03%)
CSCO : 48.68 (+1.29%)
TJX : 98.75 (-0.06%)
CPRT : 54.59 (-0.27%)
WMT : 60.41 (-0.12%)
Jobs Figures Roll out Next Week Baystreet - Sat Mar 30, 1:59PM CDT

Monday U.S. Economic Lookahead S&P U.S. manufacturing PMI (final) (Mar.) Construction ...

PVH : 113.55 (-0.40%)
SGML : 17.00 (-0.76%)
MVST : 0.4246 (-0.38%)
PAYX : 124.77 (+1.81%)
PLAY : 55.40 (+3.05%)
AYI : 261.76 (-1.12%)
LEVI : 22.68 (+0.27%)
PHVS : 21.17 (-1.35%)
RPM : 113.83 (+0.88%)
LW : 85.10 (-0.07%)
CAG : 30.95 (-0.58%)
BYRN : 13.20 (-1.57%)
Why Shares of Pharvaris N.V. Are Up Tuesday Motley Fool - Tue Jun 27, 2023

Promising news from the Food and Drug Administration spurred the healthcare stock's rise.

PHVS : 21.17 (-1.35%)
Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference Globe Newswire - Thu Jul 14, 2022

ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 21.17 (-1.35%)
Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13 Globe Newswire - Wed Jul 6, 2022

ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 21.17 (-1.35%)
Pharvaris Announces Annual Meeting of Shareholders Globe Newswire - Tue Jun 14, 2022

ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 21.17 (-1.35%)
Pharvaris Participates in the Kinin 2022 Conference Globe Newswire - Tue Jun 7, 2022

Pharvaris’ tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at satellite...

PHVS : 21.17 (-1.35%)
Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-) Globe Newswire - Mon May 16, 2022

ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 21.17 (-1.35%)
Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer Globe Newswire - Wed May 11, 2022

Pharvaris’ executive team further strengthened by Ms. Schmidt’s deep international experience and biopharmaceutical industry tenure ZUG, Switzerland, May ...

PHVS : 21.17 (-1.35%)
Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights Globe Newswire - Wed May 11, 2022

Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipated in 4Q22Enrollment...

PHVS : 21.17 (-1.35%)

Barchart Exclusives

1 'Strong Buy' Dividend Stock to Buy and Hold Barchart - Mon May 13, 6:30PM CDT
Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot